Q1 2025 saw 13% revenue growth, with Rx up 52% and TeleClinic revenue more than doubling. A CHF 200 million capital raise is fully underwritten to fund growth, with EBITDA break-even targeted in 2026 and positive free cash flow in 2027.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.